Biofrontera Inc. — Regulatory Filings 2021

Oct 20, 2021

8-A12B 1 form8a-12b.htm

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR 12(g) OF

THE SECURITIES EXCHANGE ACT OF 1934

BIOFRONTERA INC.

(Exact name of registrant as specified in its charter)

Delaware	47-3765675
(State of Incorporation or Organization)	(I.R.S. Employer Identification No.)

| 120
Presidential Way, Suite 330 Woburn,
MA | 01801 |
| --- | --- |
| (Address
of Principal Executive Offices) | (Zip
Code) |

Securities to be registered pursuant to Section 12(b) of the Act:

| Title
of Each Class to
be so Registered | Name
of Each Exchange on Which Each
Class is to be Registered |
| --- | --- |
| Common
Stock, par value $0.001 value per share | The
Nasdaq Stock Market LLC |

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box. ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box. ☐

If this form relates to the registration of a class of securities with a Regulation A offering, check the following box. ☐

Securities Act registration statement file number to which this form relates: 333-257722

Securities to be registered pursuant to Section 12(g) of the Act: None.

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 1: Description of Registrant’s Securities to be Registered

The description of the common stock, par value $0.001 per share (the “Common Stock”), of Biofrontera Inc. (the “Company”), to be registered hereunder is contained in the section titled “Description of Capital Stock” in the prospectus forming a part of the Company’s Registration Statement on Form S-1 (File No. 333-257722), as originally filed with the Securities and Exchange Commission on July 6, 2021, as thereafter amended and supplemented from time to time, including any form of prospectus contained therein pursuant to Rule 424(b) under the Securities Act of 1933, as amended, is incorporated by reference herein.

Item 2: Exhibits

Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Company are listed on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

Field: Page; Sequence: 2

Field: /Page

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

| BIOFRONTERA
INC. | |
| --- | --- |
| By: | /s/
Erica L. Monaco |
| Name: | Erica
L. Monaco |
| Title: | Chief
Financial Officer and Chief Operating Officer |

Date: October 20, 2021

Field: Page; Sequence: 3; Options: Last

Field: /Page